DelveInsight’s “Sporadic Inclusion Body Myositis (sIBM) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Sporadic Inclusion Body Myositis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Sporadic Inclusion Body Myositis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Sporadic Inclusion Body Myositis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Sporadic Inclusion Body Myositis (sIBM): An Overview
According to The Myositis Association, Sporadic inclusion body myositis (sIBM) is an acquired progressive muscle disorder that is seen normally during adulthood. sIBM can progress to cause severe disability. sIBM is an autoimmune disease mediated by cytotoxic T cells, but the exact cause of the disorder is unknown.
It is believed that multiple immunological, genetic, and environmental factors and factors related to aging all play a role in the development of the disorder and also two distinct processes autoimmune and degenerative occur in individuals with sIBM. It appears likely that autoimmunity drives the disease and accounts for the minor degenerative pathological changes seen in skeletal muscle.
The symptoms and progression of sIBM vary from one person to another. The commonly observed ones are frequent falls difficulty in walking, trouble climbing stairs or standing from a seated position, a foot seems to drop when walking, causing tripping, weakened hand grip and difficulty flexing the fingers, difficulty writing, manipulating keys, and other daily activities, weakness and noticeable shrinking of the quadriceps (main muscle of the thighs), forearm muscles and pain or discomfort as muscles weaken.
Sporadic Inclusion Body Myositis (sIBM) Market Key Facts
-
A male predominance and a prevalence of 1–71 people per million inhabitants has been reported in different populations, rising up to 139 per million among people over 50 years old as per a study “Sporadic inclusion body myositis: the genetic contributions to the pathogenesis” conducted by Gang et al.
-
As per Orphanet, the Prevalence of IBM in the general population ranges from 1:1,000,000 to 1:14,000 but a three-fold increase is observed when considering only a population over 50 years. Under diagnosis may be an explanation for the high ethno-geographic variation. The male-to-female ratio is 2:1 on average (0.5 to 6.5:1).
Sporadic Inclusion Body Myositis (sIBM) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Sporadic Inclusion Body Myositis pipeline therapies. It also thoroughly assesses the Sporadic Inclusion Body Myositis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Sporadic Inclusion Body Myositis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Sporadic Inclusion Body Myositis (sIBM) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Sporadic Inclusion Body Myositis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Sporadic Inclusion Body Myositis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Sporadic Inclusion Body Myositis Epidemiology, Segmented as –
-
Prevalent Cases of Sporadic Inclusion Body Myositis (sIBM) in 7MM (2019–2032)
-
Gender-Specific Prevalent Cases of Sporadic Inclusion Body Myositis (sIBM) in 7MM (2019–2032)
-
Diagnosed and Treatable Cases of Sporadic Inclusion Body Myositis (sIBM) in the 7MM (2019–2032)
Sporadic Inclusion Body Myositis (sIBM) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Sporadic Inclusion Body Myositis market or expected to be launched during the study period. The analysis covers the Sporadic Inclusion Body Myositis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Sporadic Inclusion Body Myositis drugs based on their sale and market share.
The report also covers the Sporadic Inclusion Body Myositis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Sporadic Inclusion Body Myositis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Sporadic Inclusion Body Myositis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/sporadic-inclusion-body-myositis-sibm-market
Sporadic Inclusion Body Myositis (sIBM) Therapeutics Analysis
The last few years have witnessed important progress in the understanding of IBM. These advances may lead to improved diagnosis and the discovery of effective drug treatments in the future. Nevertheless, the disease-triggering events and the exact way how the various disease pathways interact remain to be elucidated. The growing interest of the scientific community and new therapeutic approaches being tested in clinical trials allows us to be hopeful and confident about the future and in the ultimate goal of translating research findings into improved patient care.
Sporadic Inclusion Body Myositis (sIBM) Companies Actively Working in the Therapeutics Market Include
-
Novartis
-
Orphazyme
-
Dalazatide
And Many Others
Emerging and Marketed Sporadic Inclusion Body Myositis (sIBM) Therapies Covered in the Report Include:
-
Bimagrumab (BYM338)
-
Arimoclomol
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/sporadic-inclusion-body-myositis-sibm-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Sporadic Inclusion Body Myositis Competitive Intelligence Analysis
4. Sporadic Inclusion Body Myositis Market Overview at a Glance
5. Sporadic Inclusion Body Myositis Disease Background and Overview
6. Sporadic Inclusion Body Myositis Patient Journey
7. Sporadic Inclusion Body Myositis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Sporadic Inclusion Body Myositis Treatment Algorithm, Current Treatment, and Medical Practices
9. Sporadic Inclusion Body Myositis Unmet Needs
10. Key Endpoints of Sporadic Inclusion Body Myositis Treatment
11. Sporadic Inclusion Body Myositis Marketed Therapies
12. Sporadic Inclusion Body Myositis Emerging Drugs and Latest Therapeutic Advances
13. Sporadic Inclusion Body Myositis Seven Major Market Analysis
14. Attribute Analysis
15. Sporadic Inclusion Body Myositis Market Outlook (In US, EU5, and Japan)
16. Sporadic Inclusion Body Myositis Companies Active in the Market
17. Sporadic Inclusion Body Myositis Access and Reimbursement Overview
18. KOL Views on the Sporadic Inclusion Body Myositis Market
19. Sporadic Inclusion Body Myositis Market Drivers
20. Sporadic Inclusion Body Myositis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/sporadic-inclusion-body-myositis-sibm-market
Unlocking Insights, Driving Success: Discover DelveInsight’s Comprehensive Market Research and Consulting Services @ Healthcare Market Research
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices